Ramsey-based ADMA Biologics Inc. announced Thursday pricing for its initial public offering.
According to the announcement, the biopharmaceutical company will offer 3.35 million shares of its common stock at a public offering price of $8.50 per share. The company has granted the underwriters a 30-day option to purchase up to an additional 502,941 shares of common stock at the same price to cover over-allotments, if any.
Oppenheimer & Co. is acting as sole book-running manager for the offering. Ladenburg Thalmann & Co. Inc., Maxim Group LLC and Laidlaw & Co. Ltd. are acting as co-managers. The offering is expected to close on Oct. 22, subject to customary closing conditions, the company said in a statement.